Bristol-Myers Squibb (NYSE:BMY) Shares Sold by KPP Advisory Services LLC

KPP Advisory Services LLC lowered its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 6,885 shares of the biopharmaceutical company’s stock after selling 480 shares during the period. KPP Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $356,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. First Foundation Advisors grew its holdings in Bristol-Myers Squibb by 20.1% in the 1st quarter. First Foundation Advisors now owns 3,270 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 548 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Bristol-Myers Squibb by 76.1% in the first quarter. Acadian Asset Management LLC now owns 620,324 shares of the biopharmaceutical company’s stock worth $33,632,000 after purchasing an additional 268,006 shares in the last quarter. Catalytic Wealth RIA LLC increased its holdings in shares of Bristol-Myers Squibb by 33.1% during the first quarter. Catalytic Wealth RIA LLC now owns 9,086 shares of the biopharmaceutical company’s stock valued at $493,000 after purchasing an additional 2,258 shares during the period. Covestor Ltd raised its stake in shares of Bristol-Myers Squibb by 22.4% during the first quarter. Covestor Ltd now owns 5,558 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 1,019 shares in the last quarter. Finally, Bahl & Gaynor Inc. raised its stake in shares of Bristol-Myers Squibb by 2.7% during the first quarter. Bahl & Gaynor Inc. now owns 44,568 shares of the biopharmaceutical company’s stock valued at $2,417,000 after purchasing an additional 1,183 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of several research analyst reports. Barclays raised their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Sanford C. Bernstein assumed coverage on shares of Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective on the stock. Jefferies Financial Group boosted their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Citigroup increased their price target on Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $54.07.

Insider Transactions at Bristol-Myers Squibb

In other news, SVP Phil M. Holzer sold 700 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares in the company, valued at $654,091.20. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the purchase, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 3.04 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $56.22 on Friday. The stock’s fifty day simple moving average is $52.73 and its 200-day simple moving average is $47.25. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The company has a market capitalization of $114.02 billion, a price-to-earnings ratio of -15.66, a P/E/G ratio of 15.83 and a beta of 0.44. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.00 EPS. On average, sell-side analysts predict that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were paid a $0.60 dividend. The ex-dividend date was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.27%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -66.85%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.